Profile data is unavailable for this security.
About the company
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
- Revenue in USD (TTM)0.00
- Net income in USD-24.86m
- Incorporated2014
- Employees28.00
- LocationCorvus Pharmaceuticals Inc863 Mitten Rd Ste 102BURLINGAME 94010-1311United StatesUSA
- Phone+1 (650) 900-4520
- Fax+1 (302) 655-5049
- Websitehttps://www.corvuspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adicet Bio Inc | 0.00 | -139.79m | 121.62m | 143.00 | -- | 0.4699 | -- | -- | -2.95 | -2.95 | 0.00 | 3.15 | 0.00 | -- | -- | 0.00 | -46.75 | -37.03 | -49.70 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Tevogen Bio Holdings Inc | 0.00 | -67.33k | 128.57m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
| Biostem Technologies Inc | 58.01m | 159.39k | 128.90m | 67.00 | -- | 19.56 | 335.71 | 2.22 | -0.0865 | -0.0865 | 3.60 | 0.4064 | 2.38 | 5.17 | 2.78 | -- | 0.6536 | -- | 9.45 | -- | 94.16 | -- | 0.2748 | -- | 1.10 | 1.23 | 0.3959 | -- | -- | -- | -- | -- | -- | -- |
| Gossamer Bio Inc | 0.00 | -172.58m | 130.98m | 135.00 | -- | 4.90 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -24.86m | 131.98m | 28.00 | -- | 3.10 | -- | -- | -0.5113 | -0.5113 | 0.00 | 0.6804 | 0.00 | -- | -- | 0.00 | -50.58 | -38.31 | -59.70 | -43.34 | -- | -- | -- | -- | -- | -12.88 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Syros Pharmaceuticals Inc | 6.98m | -144.49m | 133.64m | 68.00 | -- | 8.88 | -- | 19.14 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| CytomX Therapeutics Inc | 119.18m | 16.53m | 136.36m | 120.00 | 8.85 | -- | 7.34 | 1.14 | 0.1978 | 0.1978 | 1.53 | -0.4649 | 0.5684 | -- | 16.71 | 993,150.00 | 7.89 | -21.53 | 26.77 | -32.32 | -- | -- | 13.87 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 138.32m | 217.00 | -- | 1.02 | -- | 43.51 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| FitLife Brands Inc | 58.51m | 7.30m | 140.57m | 37.00 | 20.67 | 4.78 | 18.97 | 2.40 | 1.48 | 1.48 | 11.87 | 6.39 | 1.20 | 3.87 | 27.13 | 1,581,351.00 | 15.03 | 26.40 | 19.37 | 33.92 | 41.55 | 42.09 | 12.48 | 17.65 | 0.5177 | 12.32 | 0.3582 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| I-Mab ADR | 3.82m | -202.67m | 140.74m | 220.00 | -- | 0.591 | -- | 36.82 | -2.44 | -2.44 | 0.0459 | 2.94 | 0.0083 | -- | -- | 17,375.28 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
| Rapt Therapeutics Inc | 0.00 | -118.05m | 140.94m | 126.00 | -- | 1.08 | -- | -- | -3.07 | -3.07 | 0.00 | 3.76 | 0.00 | -- | -- | 0.00 | -58.42 | -46.30 | -65.33 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Veru Inc | 13.48m | -35.82m | 141.47m | 189.00 | -- | 3.13 | -- | 10.50 | -0.3465 | -0.3465 | 0.1267 | 0.3089 | 0.1898 | 1.42 | 3.86 | 71,318.68 | -50.43 | -42.91 | -76.84 | -54.41 | 34.13 | 72.41 | -265.74 | -104.96 | 4.22 | -- | 0.177 | -- | -58.59 | 0.5394 | -10.84 | -- | 67.39 | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 142.19m | 179.00 | -- | 0.6077 | -- | 1.45 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Cardiff Oncology Inc | 610.00k | -40.25m | 142.22m | 31.00 | -- | 2.33 | -- | 233.15 | -0.901 | -0.901 | 0.0137 | 1.36 | 0.0068 | -- | 1.14 | 19,677.42 | -44.55 | -31.24 | -50.10 | -33.56 | -- | -- | -6,594.92 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
Data as of May 31 2024. Currency figures normalised to Corvus Pharmaceuticals Inc's reporting currency: US Dollar USD
21.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Point72 Asset Management LPas of 02 May 2024 | 5.96m | 12.16% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.48m | 3.02% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 637.03k | 1.30% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 516.07k | 1.05% |
| TowerView LLCas of 31 Mar 2024 | 382.50k | 0.78% |
| Geode Capital Management LLCas of 31 Mar 2024 | 371.76k | 0.76% |
| BVF Partners LPas of 31 Mar 2024 | 361.41k | 0.74% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 271.84k | 0.55% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 224.30k | 0.46% |
| Two Sigma Advisers LPas of 31 Mar 2024 | 185.10k | 0.38% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
